LVTX

LAVA Therapeutics N.V.

2.60 USD
-0.01 (-0.38%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

LAVA Therapeutics N.V. stock is down -10.34% since 30 days ago. The next earnings date is Aug 20, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 3 May’s closed higher than April.

About LAVA Therapeutics N.V.

LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. LAVA-051 is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia.